> Our Mission


We strive to improve the lives of individuals and families living with Parkinson's disease and other neurological disorders through collaborative scientific, medical, and healthcare advancements that deliver safe and efficacious gene therapies for slowing or reversing disease progression.

> Our Focus


Brain Neurotherapy Bio is focused on the clinical translation and development of neurotrophic factor gene therapy for the treatment of Parkinson’s disease and other neurological conditions. Our initial clinical program will expand upon the safety and evaluate the preliminary efficacy of glial cell line-derived neurotrophic factor (GDNF) gene therapy in patients with Parkinson’s disease. This program utilizes a clinically-proven AAV gene therapy platform that incorporates novel image-guided neurosurgical delivery technology to optimize the precision, safety and efficiency of gene transfer within the brain. Our vision is to provide people afflicted with neurological disorders with increased access to transformative gene therapies for slowing or reversing disease progression.

The Company

Developing transformative neurological gene therapies that restore and preserve health and well-being.

Our Science

Advancing disease-modifying gene therapy for neurological diseases.

Our Partners

Stronger through multidisciplinary collaboration.

> Our Science


Gene therapy directly administered to the brain features the delivery of an engineered gene  packaged within a carrier particle, that allows targeting and influence of specific populations of brain cells. We take advantage of optimized AAV gene transfer technology and advanced neurosurgical methods to precisely deliver therapeutic genes within the brain. Following incorporation of the desired DNA sequences, or genes, within targeted brain cells, the DNA harnesses intrinsic cell machinery to produce the therapeutic product. In the Parkinson's disease study, this product would be GDNF that is used by targeted brain cells to enhance function and maintain viability of specific brain cells and their associated networks.

Read More


The Science of Parkinson’s


Bayer doubles down on Parkinson’s?

Brain Neurotherapy Bio merges with Asklepios BioPharmaceutical to jointly advance central nervous system gene therapies


Brain Neurotherapy Bio, Inc. (BNB), a private clinical-stage gene therapy development company, has reached an agreement to merge and become a wholly-owned subsidiary of Asklepios BioPharmaceutical, Inc. (AskBio), a Bayer company headquartered in North Carolina, specializing in the research, development and manufacturing of gene therapies across a variety of therapeutic indications.

Brain Neurotherapy Bio, Inc. Announces Treatment of First Patient in New GDNF Gene
Therapy Trial for Parkinson’s Disease


COLUMBUS, OHIO and OAKLAND, CALIFORNIA, August 25, 2020 - - Brain Neurotherapy Bio, Inc. (BNB), a clinical stage biotechnology company focused on advancing central nervous system gene therapies for neurological disorders, today announced treatment of the first Parkinson’s disease patient in a Phase 1b glial cell line-derived neurotrophic factor (GDNF) gene therapy study.

Stem Cell Agency Approves Funding for Clinical Trials Targeting Parkinson’s Disease and Blindness


Oakland, CA – The governing Board of the California Institute for Regenerative Medicine (CIRM) today invested $32.92 million to fund the Stem Cell Agency’s first clinical trial in Parkinson’s disease (PD), and to support three clinical trials targeting different forms of vision loss.


Brain Neurotherapy Bio, Inc. Copyright © 2020. All Rights Reserved